Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Emricasan leads to liver gains
June 2019
SHARING OPTIONS:

SAN DIEGO—Conatus Pharmaceuticals Inc. recently published data in Hepatology Communications regarding emricasan, its first-in-class pan-caspase inhibitor. In rats with advanced cirrhosis, including increased portal pressure induced by chronic carbon tetrachloride administration, seven-day treatment resulted in a significant drop in portal pressure compared to vehicle-treated control rats, and this reduction was linked to improved liver function, reduced liver inflammation and reduced fibrosis. Rats treated with emricasan also saw improvement in expression of markers of liver function, such as increased expression of vasodilators and reduced expression of vasoconstrictors. When human cirrhotic liver cells were treated in vitro with emricasan, it improved the synthetic capacity of hepatocytes and boosted expression of markers of liver function.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.